Retatrutide Long-Term Safety: 2-Year Follow-Up Data from Phase 3 Trials

Introduction

TRIUMPH-4 showed 28.7% weight loss at 68 weeks. TRIUMPH-1 confirmed 28.3% in 2,339 general obesity patients at 80 weeks — and a prespecified 104-week extension showed average loss reaching 30.3%. That's impressive data. But obesity is a chronic disease requiring years of treatment, not months. The real question isn't what happens at week 68 or week 80 — it's what happens at year 3, year 5, and beyond.

As of June 2026, we now have the longest retatrutide data from TRIUMPH-1's 104-week extension (BMI ≥35 subgroup). That's our best window into what extended treatment looks like. Full 2-year published safety data for the broader population is still pending. TRIUMPH-CVOT results are years away. Here's what the current data shows:

Source: TRIUMPH-4 (N=751, 12mg dose, 68 weeks) and TRIUMPH-1 (N=2,339, 80 weeks + 104-week extension). Individual risk varies based on medical history and concurrent medications.

What We Know: Safety Data Through 80–104 Weeks

Status as of June 2026:

The longest published retatrutide data now comes from TRIUMPH-1 at 80 weeks (with a 104-week extension for the BMI ≥35 subgroup). In 2,339 participants at the 12mg dose, the safety profile was consistent with TRIUMPH-4 and GLP-1 class expectations — with one important improvement: discontinuation due to side effects dropped to 11.3%, compared to 18.2% in TRIUMPH-4's osteoarthritis population.

Most common side effects (12mg dose, across TRIUMPH-4 and TRIUMPH-1):

• Nausea: 43% TRIUMPH-4 / ~38% TRIUMPH-1 (mostly during dose escalation)
• Diarrhea: 33% / ~28% (peaks weeks 4–8, improves by week 16)
• Dysesthesia: 20.9% (tingling sensations — onset variable, long-term persistence unknown)
• Vomiting: 18% / ~15% (decreases after month 3)
• Constipation: 12%

Discontinuation rates: 18.2% in TRIUMPH-4 (osteoarthritis population), 11.3% in TRIUMPH-1 (general obesity population). This is an important distinction — the osteoarthritis cohort was older and more comorbid. The 11.3% rate in a general obesity population is now comparable to tirzepatide (14.9%).

Serious adverse events: 8–10% of participants experienced a serious adverse event (SAE). The most common were gallbladder-related issues (cholecystitis, cholelithiasis) at 2.4%, consistent with other GLP-1 medications. Pancreatitis occurred in less than 1% of participants.

No deaths occurred in TRIUMPH-4 or TRIUMPH-1 attributable to retatrutide.

The critical limitation: Even 80–104 weeks is not "long-term" for a chronic disease medication. We need 5-year and 10-year data to fully understand retatrutide's safety profile over the duration most patients will require. That data is years away.

Sustained Weight Loss: Does It Plateau or Continue?

TRIUMPH-4 showed continued weight loss through week 68. TRIUMPH-1 extended this picture significantly:

TRIUMPH-4 trajectory (68 weeks):

• Week 24: 17.3% weight loss
• Week 48: 24.2% weight loss
• Week 68: 28.7% weight loss

TRIUMPH-1 trajectory (80 weeks + extension):

• Week 80: 28.3% average weight loss (2,339 patients)
• 104-week extension (BMI ≥35 subgroup): 30.3% average weight loss
• Weight loss does not plateau at 80 weeks — it continues in longer treatment

The TRIUMPH-1 104-week extension is the most important long-term efficacy signal we have. Patients who continued treatment into year two not only maintained their weight loss but continued to lose additional weight, reaching 30.3% in the high-BMI subgroup. This is higher than what tirzepatide achieves even at its best.

Comparison to tirzepatide (Mounjaro/Zepbound):

Tirzepatide's SURMOUNT-1 trial (72 weeks) showed 22.5% weight loss at endpoint. Extended follow-up through 88 weeks showed the plateau occurring around week 72–76. Retatrutide's 104-week extension data suggests a later plateau — consistent with the glucagon mechanism's ongoing metabolic effects.

What we'd expect long-term based on available data:

• Weight loss continues through at least 104 weeks in most patients
• Estimated peak loss: 30–32% in patients reaching maximum dose and maintaining treatment
• Maintenance phase: stable weight if treatment continues without dose reduction

Weight regain after stopping is near-universal with all GLP-1 medications. Semaglutide's STEP 1 trial showed participants regained two-thirds of lost weight within one year of stopping. Retatrutide will likely follow the same pattern — this is a chronic medication, not a temporary intervention.

Dysesthesia: The Long-Term Question Mark

Dysesthesia — the altered sensation or tingling side effect — is retatrutide's unique long-term concern. It occurred in 20.9% of TRIUMPH-4 participants and was observed in TRIUMPH-1 as well, confirming it's not a TRIUMPH-4 artifact.

What dysesthesia looks like:

• Tingling or "pins and needles" sensations, most commonly in hands, feet, or face
• Altered temperature sensation
• Burning or prickling sensations
• Onset typically during dose escalation (weeks 4–16) but can occur later

Severity: Most cases were mild and didn't lead to treatment discontinuation. About 1–2% of participants stopped retatrutide specifically due to dysesthesia.

Dysesthesia is the most distinctive and least understood side effect of retatrutide. For detailed information on this unusual sensation, potential mechanisms, and patient experiences, see our complete dysesthesia guide.

The critical unknown: Does it persist long-term?

TRIUMPH-4 and TRIUMPH-1 tracked dysesthesia occurrence but didn't systematically follow whether it resolved after treatment. Some participants reported resolution by week 40–50. Others still experienced symptoms at trial endpoint. We don't yet know:

• What percentage of dysesthesia cases resolve vs. persist long-term?
• Does continued treatment worsen, improve, or stabilize symptoms?
• Do symptoms resolve after stopping retatrutide, or persist?
• Is there permanent nerve involvement, or is it fully reversible?

Why this matters: If dysesthesia persists indefinitely in even 5–10% of users, that's a significant long-term quality-of-life concern for what is intended as a lifelong medication.

Mechanistic hypothesis: Dysesthesia is likely related to glucagon receptor activation, which retatrutide targets uniquely among obesity medications. Glucagon affects peripheral nerve function and blood flow.

What to monitor if on retatrutide and experiencing dysesthesia:

• When it started (which dose, which week)
• Severity progression (stable, worsening, improving)
• Impact on daily activities
• Response to dose reduction

Report persistent or worsening dysesthesia to your doctor. Some patients report improvement with dose reduction or temporary treatment interruption.

Cardiovascular Safety: Long-Term Heart Health

GLP-1 receptor agonists have demonstrated cardiovascular benefits in long-term trials. Semaglutide reduced major adverse cardiovascular events (MACE) by 20% in the SELECT trial. Tirzepatide's ongoing SURPASS-CVOT trial will provide similar data.

Retatrutide's cardiovascular trial: TRIUMPH-CVOT is ongoing, enrolling patients with obesity and established cardiovascular disease. Primary endpoint is MACE (cardiovascular death, myocardial infarction, stroke). Expected completion: 2028–2029.

What we know from TRIUMPH-4 (blood pressure through 68 weeks):

• Systolic BP: -8.0 mmHg average reduction
• Diastolic BP: -4.3 mmHg average reduction

These reductions persisted even as weight loss plateaued in the final weeks, suggesting blood pressure benefits may be partially independent of weight — possibly due to direct GLP-1 and glucagon receptor effects on vascular function.

Heart rate: Increased by an average of 5–7 beats per minute, consistent with other GLP-1 medications. Generally benign but requires monitoring in patients with pre-existing arrhythmias.

Lipid profile improvements (TRIUMPH-4):

• LDL cholesterol: -8% reduction
• Triglycerides: -22% reduction
• HDL cholesterol: +12% increase

The triglyceride reduction is particularly notable and likely related to glucagon receptor activation, which enhances fat oxidation. All surrogate markers point in a favorable cardiovascular direction.

Long-term cardiovascular unknowns:

Does retatrutide reduce cardiovascular events like semaglutide does, or is the benefit purely from weight loss? TRIUMPH-CVOT will answer this, but results are 2–3 years away. For now, the metabolic profile (blood pressure, lipids, weight loss) is strongly favorable.

Gastrointestinal Effects: Tolerance and Adaptation

Nausea and diarrhea are the most common side effects, but they follow a predictable pattern:

Weeks 1–8 (dose escalation): Highest incidence. Nausea peaked at 43–48% during weeks 4–6. Diarrhea peaked at 33–38% during the same period.

Weeks 8–24: Gradual improvement. By week 16, nausea had decreased to ~22% and diarrhea to ~18%.

Weeks 24–68+: Stable and low. By week 24, only 8–12% reported ongoing nausea, and most rated it as mild. Diarrhea stabilized at 6–8%. TRIUMPH-1 confirms this pattern holds through 80 weeks.

Long-term management strategies:

• Slow dose escalation (extend any phase if needed)
• Take medication with food
• Avoid high-fat meals during dose increases
• Stay hydrated
• Over-the-counter anti-nausea aids (ginger, vitamin B6)

For comprehensive side effect management information, see our complete side effects guide.

Gallbladder concerns:

Retatrutide showed a 2.4% rate of gallbladder-related adverse events over 68 weeks. This is slightly higher than the general population (0.5–1% annually) but consistent with other weight-loss medications. The risk is related to the speed and magnitude of weight loss rather than a direct drug effect.

Who's at higher risk:

• Rapid weight loss (>2–3 pounds per week sustained)
• Personal or family history of gallstones
• Female sex, age >40
• Pre-existing obesity (higher baseline gallstone risk)

Metabolic Effects: Glucose Control and Diabetes Prevention

TRIUMPH-4 included both participants with and without type 2 diabetes. Metabolic improvements were substantial and sustained:

HbA1c reduction (diabetic participants through 68 weeks):

• Baseline: 8.1% average
• Week 24: 6.2%
• Week 68: 5.9%

About 78% achieved HbA1c <7% (diabetes treatment target), and 42% achieved <5.7% (non-diabetic range).

Fasting glucose reduction:

• Diabetic participants: -58 mg/dL average
• Non-diabetic participants: -12 mg/dL average

Diabetes prevention potential:

Among participants with prediabetes at baseline (HbA1c 5.7–6.4%), 89% reverted to normal glucose tolerance by week 68. Only 1.2% progressed to diabetes during the trial. TRIUMPH-1's 80-week data shows these metabolic improvements are maintained.

Long-term unknowns:

• Do these metabolic improvements persist beyond 80–104 weeks?
• Does retatrutide prevent diabetes long-term, or just delay it?
• What happens when treatment is stopped?

Based on tirzepatide data (sustained HbA1c reductions through 88 weeks), we'd expect metabolic benefits to persist as long as treatment continues.

Cancer Risk: Theoretical Concerns and Current Data

GLP-1 receptor agonists have been scrutinized for potential cancer risk:

1. Thyroid C-cell tumors seen in rodent studies (medullary thyroid carcinoma)
2. Pancreatitis concerns, which theoretically increase pancreatic cancer risk
3. Rapid cell turnover during weight loss

Current retatrutide data (TRIUMPH-4 and TRIUMPH-1):

• Thyroid cancer: 0 cases
• Pancreatic cancer: 0 cases
• Other cancers: within expected population rates

The rodent thyroid tumor issue:

All GLP-1 receptor agonists cause C-cell hyperplasia in rats at high doses. However, human thyroid C-cells express far fewer GLP-1 receptors than rodent cells. After 10+ years of semaglutide and liraglutide use in millions of patients, no thyroid cancer signal has emerged in humans.

Retatrutide carries the same FDA black box warning as other GLP-1 medications: contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Pancreatitis and pancreatic cancer:

Acute pancreatitis occurred in <1% of trial participants. Long-term studies of semaglutide and liraglutide (10+ years of post-market surveillance) have not shown increased pancreatic cancer risk.

What we don't know for retatrutide:

Does the glucagon receptor activation change cancer risk compared to pure GLP-1 agonists? We simply don't have long-term data yet. Standard cancer screening based on age and risk factors is recommended — no additional screening is currently warranted.

Comparison to Other Weight-Loss Medications

Note: Discontinuation rates from respective pivotal trials at highest approved doses.

Key takeaways:

1. Retatrutide's discontinuation rate in TRIUMPH-1 (11.3%) is now comparable to tirzepatide (14.9%) — better than TRIUMPH-4 (18.2%) suggested.
2. Serious adverse event rates are comparable across all medications.
3. Dysesthesia is retatrutide-specific — the main safety differentiator.
4. Longer-term real-world data exists for competitors: semaglutide has 8+ years of market use. Retatrutide's longest data is ~104 weeks.
5. The efficacy-tolerability trade-off: retatrutide produces superior weight loss (28.3–30.3%) with moderate tolerability.

What Happens After Stopping Treatment?

This is perhaps the most important long-term question for patients.

Data from semaglutide (STEP 4 withdrawal study):

• Average weight regain after stopping: 11.6% of body weight (about two-thirds of what was lost)
• Metabolic improvements largely reversed
• GI side effects resolved within 2–4 weeks of stopping

Tirzepatide shows similar patterns based on preliminary data.

Why weight regain occurs:

GLP-1 receptor agonists don't cure obesity — they suppress appetite while you're taking them. When you stop, appetite returns to baseline (or higher, as the body tries to restore lost weight). The "set point" theory: your body defends a certain weight range through hormonal and metabolic adaptations that persist long after weight loss.

What this means for retatrutide:

We don't have official withdrawal data yet, but based on the mechanism, weight regain after stopping is near-certain. The glucagon component might make the metabolic drop sharper than with pure GLP-1 agonists — glucagon increases metabolic rate while on treatment.

Potential strategies to minimize regain:

1. Gradual dose tapering over 3–6 months (limited data)
2. Transition to lower-efficacy but better-tolerated maintenance medication
3. Intensive lifestyle intervention (10–20% success rate at maintaining most weight loss)

The hard truth: for most people, retatrutide is likely lifelong treatment if you want to maintain weight loss. This is the biology of obesity, not a failure of willpower.

Who Should Not Take Retatrutide: Long-Term Contraindications

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy within 2 months
• Severe gastroparesis or GI motility disorders
• History of severe pancreatitis

Relative contraindications (use with caution):

• History of gallbladder disease or gallstones
• Diabetic retinopathy (rapid glucose reduction can worsen retinal changes)
• Severe kidney disease
• History of eating disorders
• Pre-existing peripheral neuropathy (dysesthesia adds to existing nerve symptoms)
• Heart failure with reduced ejection fraction (limited data)

Age considerations:

TRIUMPH-4 and TRIUMPH-1 included participants up to age 75. Older adults face higher baseline risk for falls (potentially worsened by dysesthesia), malnutrition (if appetite suppression is too severe), and polypharmacy interactions.

Medication interactions requiring monitoring:

• Insulin and sulfonylureas (hypoglycemia risk — may need dose reduction)
• Warfarin (GI effects can alter vitamin K absorption)
• Oral medications requiring careful timing (retatrutide slows gastric emptying)

Monitoring During Long-Term Treatment

Baseline (before starting):

• Comprehensive metabolic panel (kidney and liver function)
• HbA1c and fasting glucose
• Lipid panel
• Thyroid function (TSH at minimum)
• Pregnancy test (if applicable)

First 6 months (dose escalation phase):

• Weight and blood pressure every 2–4 weeks
• HbA1c at 3 months (if diabetic)
• Metabolic panel at 3 months
• Assess for dysesthesia, GI tolerance, mood changes

Months 6–12:

• HbA1c every 3–6 months
• Metabolic panel every 6 months
• Lipid panel at 12 months

Long-term (12+ months):

• HbA1c every 6 months
• Metabolic panel annually
• Lipid panel annually
• Continue weight and blood pressure tracking

Red flags requiring immediate attention:

• Severe abdominal pain (especially right upper quadrant — gallbladder)
• Signs of pancreatitis (severe upper abdominal pain radiating to back)
• Persistent vomiting (can't keep down liquids 24+ hours)
• Yellowing of skin or eyes (jaundice)
• Severe dysesthesia interfering with daily activities
• Severe depression or thoughts of self-harm
• Rapid heart rate (>120 bpm at rest)

The Unknowns: What We're Still Waiting to Learn

1. Full 2-year published safety data: TRIUMPH-1 104-week extension data is available for the BMI ≥35 subgroup, but full publication of the complete 2-year dataset is pending — expected late 2026.
2. Cardiovascular outcomes: TRIUMPH-CVOT results expected 2028–2029. Will definitively answer whether retatrutide reduces heart attacks and strokes beyond weight-loss effects.
3. Dysesthesia natural history: Does it resolve, persist, or worsen with continued treatment? Does it go away after stopping? Systematic neurological assessments are ongoing.
4. Cancer surveillance: 5–10 years of real-world data are needed to rule out rare cancer signals.
5. Pregnancy outcomes: Animal studies suggest potential harm, but human data is limited for post-exposure pregnancies.
6. Very long-term weight maintenance: Can patients maintain 30%+ weight loss on retatrutide for 5–10 years? Does efficacy decline over time (tachyphylaxis)?
7. Rare events: With ~3,000 patients on active drug across completed trials, we can't detect adverse events that occur in fewer than 1 in 1,000 people.
8. Cost-benefit at scale: If millions use retatrutide for years, do the cardiovascular and diabetes prevention benefits outweigh the side effect burden and $15,000–18,000 annual cost?

For a comprehensive overview of all TRIUMPH trials and their expected timelines, see our complete retatrutide guide.

Conclusion

Retatrutide's long-term safety profile — through 80–104 weeks of data — shows impressive metabolic benefits with an acceptable but not perfect tolerability picture.

What we know:

• GI side effects are common but typically improve after 3–6 months
• No deaths or major safety signals through 80–104 weeks across two large trials
• Metabolic improvements (glucose, blood pressure, lipids) are substantial and sustained
• Discontinuation rate: 11.3% in general obesity population (TRIUMPH-1) — better than initially feared from TRIUMPH-4's 18.2%
• 104-week extension shows continued weight loss to 30.3% — no plateau at 80 weeks

What we don't know:

• Full 2-year safety dataset (pending publication)
• Whether dysesthesia resolves or persists long-term
• Cardiovascular outcomes (trial ongoing)
• Weight regain trajectory after stopping
• Very rare adverse events requiring broader use to detect

The bottom line:

Retatrutide offers superior weight loss compared to existing medications — and TRIUMPH-1's 11.3% discontinuation rate suggests the tolerability picture is better than TRIUMPH-4's osteoarthritis cohort implied. For people who can tolerate the side effects (about 88.7% completed TRIUMPH-1), it produces remarkable results with an acceptable safety profile based on available data.

The unique triple-agonist mechanism means we're extrapolating some long-term assumptions from other GLP-1 medications. For most patients with significant obesity, the risk-benefit calculation currently favors retatrutide — but the full picture will take years of post-market data to complete.

Sources

• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results, including 104-week extension. May 21, 2026.
• Eli Lilly press release: TRIUMPH-4 Phase 3 Trial Results. December 2025.
• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine 2023;389:514–526
• Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021 (STEP 1 trial)
• Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA 2021 (STEP 4 — withdrawal study)
• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022 (SURMOUNT-1)
• ClinicalTrials.gov: TRIUMPH Phase 3 program trial protocols and status updates
• FDA Prescribing Information: Wegovy, Mounjaro/Zepbound, Saxenda (for comparative safety data)